Jian Zhang

Shanghai Medical College of Fudan University — China

Medicine · Health Sciences

17h-index1.1kcitations84works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(31), HER2/EGFR in Cancer Research(22), Cancer Treatment and Pharmacology(18), Lung Cancer Research Studies(12), Chronic Lymphocytic Leukemia Research(9)

Publications84 total

Efficacy and Safety of Treatment Beyond Progression with anti-PD-(L)1 Therapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-analysis
2025Open Access
Adverse events induced by the subcutaneous HER2-targeted antibody‑drug conjugate JSKN033 in a male patient with breast cancer: A case report
Oncology Letters·2025· 1 citedOpen Access
616 Initial safety and efficacy results from a first in human, phase 1/2 study of ASKG915, an anti-PD-1/Pro-IL-15 bifunctional fusion protein, for patients with advanced solid tumors
Regular and Young Investigator Award Abstracts·2025Open Access
1331 HCB101, a next-generation Fc-engineered anti-CD47 SIRPα fusion protein, demonstrates favorable safety and early antitumor activity in advanced cancers
2025Open Access
Abstract B008: TFX06 demonstrated intracranial efficacy in patients with ER+/HER2- brain metastatic breast cancer in a phase 1/2 study
Molecular Cancer Therapeutics·2025
Abstract PS8-08: Efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate (ADC), in 391 heavily pretreated multiple solid tumors with HER2-expression or mutations: a global, multi-center, first-in-human, phase 1 study
Clinical Cancer Research·2025
Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study.
Journal of Clinical Oncology·2025· 5 cited
A phase 1 FIH study of novel oral SERD FWD1802 in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer with or without ESR1 mutations.
Journal of Clinical Oncology·2025
SIM0270 in combination with palbociclib in patients with ER+/ HER2- advanced breast cancer: The phase Ib study.
Journal of Clinical Oncology·2025
A phase I/IIa study to evaluate the tolerability, safety, pharmacokinetics and efficacy of eciruciclib (BPI-1178) alone in advanced solid tumors and in combination with endocrine therapy for advanced or recurrent HR+/HER2- breast cancer.
Journal of Clinical Oncology·2025
Phase 1 trial of HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, in subjects with advanced cancers.
Journal of Clinical Oncology·2025
Multifunctional tumor vaccines carrying thalidomide regulate T cell exhaustion and ferroptosis for immunotherapy strategies
View·2025Open Access
Enrichment and Detection of HER2-Expressing Extracellular Vesicles Based on DNA Tetrahedral Nanostructures: A New Strategy for Liquid Biopsy in Breast Cancer
Analytical Chemistry·2025· 4 cited
Long-Term Efficacy and Safety of Anti-HER2 Antibody-Drug Conjugate SHR-A1811 in Heavily Treated HER2-Expressing or Mutated Advanced Solid Tumours: A Global Phase 1 Trial (HORIZON-X)
SSRN Electronic Journal·2025Open Access
Abstract 4144219: Safety and Efficacy of Rechallenging Immune Checkpoint Inhibitors After Discontinuation Due to Immune-Associated Myocarditis in Cancer Patients
Circulation·2024
Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC
Blood·2024· 2 citedOpen Access
Exemplifying interspecies variation of liposome in vivo fate by the effects of anti-PEG antibodies
Acta Pharmaceutica Sinica B·2024· 5 citedOpen Access
Reciprocal Interaction with Neutrophils Facilitates Cutaneous Accumulation of Liposomes
ACS Nano·2024· 9 cited
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
Journal of Clinical Oncology·2024· 32 cited
Neoadjuvant docetaxel-cisplatin followed by concurrent chemoradiotherapy and adjuvant tislelizumab for locally advanced nasopharyngeal carcinoma: A multicenter, single-arm, phase II trial.
Journal of Clinical Oncology·2024· 1 cited
page 1 of 5Next →

Frequent Co-authors

Biyun Wang(12), Xichun Hu(12), Xichun Hu(11), Leiping Wang(8), Zhonghua Tao(7), Jun Cao(6), Li‐Xin Qiu(6), Kai Xue(6), Chen Mao(5), Yanchun Meng(5), Yizi Jin(5), Zhonghua Wang(4), Yiqun Du(4), Chengcheng Gong(4), Yannan Zhao(4), Mingxi Lin(4), Junning Cao(3), Xiaojian Liu(3), Qing Chen(3), Jingfen Wang(3)